These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
142 related items for PubMed ID: 1286765
21. Regulatory considerations for marker vaccines and diagnostic tests in the U.S. Foley PL, Hill RE. Biologicals; 2005 Dec; 33(4):253-6. PubMed ID: 16257538 [Abstract] [Full Text] [Related]
22. Use of the dog as non-rodent test species in the safety testing schedule associated with the registration of crop and plant protection products (pesticides): present status. Box RJ, Spielmann H. Arch Toxicol; 2005 Nov; 79(11):615-26. PubMed ID: 15940470 [Abstract] [Full Text] [Related]
23. Duration of immunity (DOI)--The regulatory issues. Gaskell RM, Dawson S, Radford AD. Vet Microbiol; 2006 Oct 05; 117(1):80-5. PubMed ID: 16723198 [Abstract] [Full Text] [Related]
24. Some remarks on the efficacy of vaccines for veterinary use. Lensing HH. Dev Biol Stand; 1992 Oct 05; 79():43-5. PubMed ID: 1286764 [No Abstract] [Full Text] [Related]
26. Alternative methods to safety studies in experimental animals: role in the risk assessment of chemicals under the new European Chemicals Legislation (REACH). Lilienblum W, Dekant W, Foth H, Gebel T, Hengstler JG, Kahl R, Kramer PJ, Schweinfurth H, Wollin KM. Arch Toxicol; 2008 Apr 05; 82(4):211-36. PubMed ID: 18322675 [Abstract] [Full Text] [Related]
32. Licensing veterinary biologics in the United States. Espeseth DA. Dev Biol Stand; 1992 Apr 05; 79():17-25. PubMed ID: 1286752 [Abstract] [Full Text] [Related]
33. The legal foundation of the production and use of herd-specific vaccines in Europe. Attia Y, Schmerold I, Hönel A. Vaccine; 2013 Aug 12; 31(36):3651-5. PubMed ID: 23764532 [Abstract] [Full Text] [Related]
34. Regulatory requirements for veterinary vaccine stability in the European Community. Fawthrop D. Dev Biol Stand; 1996 Aug 12; 87():319-27. PubMed ID: 8854032 [Abstract] [Full Text] [Related]
35. Control and eradication of O.I.E. list A diseases--the approach of the European Union to the use of vaccines. Laddomada A. Dev Biol (Basel); 2003 Aug 12; 114():269-80. PubMed ID: 14677697 [Abstract] [Full Text] [Related]
36. Control of product batches (before and after registration). The German approach. Jungbäck C. Dev Biol Stand; 1992 Aug 12; 79():171-4. PubMed ID: 1286753 [Abstract] [Full Text] [Related]
37. OIE standards for vaccines and future trends. Edwards S. Rev Sci Tech; 2007 Aug 12; 26(2):373-8. PubMed ID: 17892158 [Abstract] [Full Text] [Related]
38. [The principle of registration, evaluation and testing of disinfecting preparations]. Röhm-Rodowald E, Jakimiak B, Podgórska M. Przegl Epidemiol; 2008 Aug 12; 62(3):661-8. PubMed ID: 19108531 [Abstract] [Full Text] [Related]
39. Stability testing requirements for vaccines--draft guidelines of the International Conference on Harmonization. Haase M. Dev Biol Stand; 1996 Aug 12; 87():309-18. PubMed ID: 8854031 [Abstract] [Full Text] [Related]
40. Analysis of reproductive toxicity and classification of glufosinate-ammonium. Schulte-Hermann R, Wogan GN, Berry C, Brown NA, Czeizel A, Giavini E, Holmes LB, Kroes R, Nau H, Neubert D, Oesch F, Ott T, Pelkonen O, Robert-Gnansia E, Sullivan FM. Regul Toxicol Pharmacol; 2006 Apr 12; 44(3 Suppl 1):S1-76. PubMed ID: 16510221 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]